Restitutio ad integrum

Growth Expert Ben Norton Joins Integrum Worldwide as SVP of Growth

Retrieved on: 
Tuesday, June 7, 2022
Magnet, University, Hilton, Leadership, University of California, Irvine, Google, PBS, MBA, Business, COO, Restitutio ad integrum, CEO, Senior, Organization, International business, UC, Solution, Singani, Mastercard, Acquisition, Operation Xcellerator, Google Analytics, Population, LOS, Efficiency, Internet, Urchin, Management, Growth

LOS ANGELES, June 7, 2022 /PRNewswire/ -- Integrum Worldwide, the global marketing agency collective backed by Apollo Capital Corp and M2B Growth Enterprises, today announced that Ben Norton has recently joined the company as Senior Vice President of Growth. Norton adds to an exceptional leadership team that supports Integrum's two agencies Storia and Chalk and will be responsible for leading all growth initiatives across the rapidly expanding collective of agencies.

Key Points: 
  • Norton's tenure working in business development, sales leadership, and growth strategy across both brands and agencies makes Norton an obvious addition to lead Integrum Worldwide's growth plans.
  • LOS ANGELES, June 7, 2022 /PRNewswire/ -- Integrum Worldwide , the global marketing agency collective backed by Apollo Capital Corp and M2B Growth Enterprises, today announced that Ben Norton has recently joined the company as Senior Vice President of Growth.
  • As an executive leader with more than 20 years of experience, Ben Norton is an expert in business development, sales leadership, account management, digital marketing, growth strategy execution and corporate development.
  • Since joining the Integrum Worldwide team, the organization has seen significant growth and is actively hiring to add to its new business team across the collective.

Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Tuesday, May 24, 2022
HCC, Neoplasm, Toxic epidermal necrolysis, Tumor microenvironment, TCON, Patient, CD40, NASDAQ, PD-1, Cancer, Restitutio ad integrum, NSCLC, Research, Mouse, Partnership, PDAC, Hepatocellular carcinoma, Large-cell lung carcinoma, Immunoglobulin G, Pharmacodynamics, Mab, Hepatotoxicity, Pharmaceutical industry

Pharmacodynamic studies in mice indicate that YH003 significantly increased the infiltration of anti-tumor T cells into tumors.

Key Points: 
  • Pharmacodynamic studies in mice indicate that YH003 significantly increased the infiltration of anti-tumor T cells into tumors.
  • Currently, YH003 is undergoing phase II multi-regional clinical trials (MRCTs) for the treatment of patients with unresectable/metastatic melanoma and pancreatic ductal adenocarcinoma (PDAC).
  • As a wholly owned subsidiary of Biocytogen, Eucure Biopharma undertakes the mission of clinical development for Biocytogen's R&D pipelines.
  • Relying on a strong clinical development team and extensive clinical development experience, Eucure Biopharma focuses on antibody drug therapy for oncology and other indications.

Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Tuesday, May 24, 2022
HCC, Neoplasm, Toxic epidermal necrolysis, Tumor microenvironment, TCON, Patient, CD40, NASDAQ, PD-1, Cancer, Restitutio ad integrum, NSCLC, Research, Mouse, Partnership, PDAC, Hepatocellular carcinoma, Large-cell lung carcinoma, Immunoglobulin G, Pharmacodynamics, Mab, Hepatotoxicity, Pharmaceutical industry

Pharmacodynamic studies in mice indicate that YH003 significantly increased the infiltration of anti-tumor T cells into tumors.

Key Points: 
  • Pharmacodynamic studies in mice indicate that YH003 significantly increased the infiltration of anti-tumor T cells into tumors.
  • Currently, YH003 is undergoing phase II multi-regional clinical trials (MRCTs) for the treatment of patients with unresectable/metastatic melanoma and pancreatic ductal adenocarcinoma (PDAC).
  • As a wholly owned subsidiary of Biocytogen, Eucure Biopharma undertakes the mission of clinical development for Biocytogen's R&D pipelines.
  • Relying on a strong clinical development team and extensive clinical development experience, Eucure Biopharma focuses on antibody drug therapy for oncology and other indications.

Biocytogen Enters into Antibody Agreement with Merck KGaA, Darmstadt, Germany

Retrieved on: 
Friday, April 29, 2022
Antibody, Entrepreneurship, Intelligence, CEO, Restitutio ad integrum, Electronics, Merck Millipore, Patient, Gene editing, Merck, Health, Merck Group, Therapy, Multimedia, Science, View, Research, Merck Serono, Fine chemical, Vaccine, Pharmaceutical industry

Under the agreement, Biocytogen will provide Merck KGaA, Darmstadt, Germany antibodies directed against at least three targets specified by them from Biocytogen's Project Integrum(also called HiTS Platform), which are generated by leveraging Biocytogen's proprietary RenMicePlatform.

Key Points: 
  • Under the agreement, Biocytogen will provide Merck KGaA, Darmstadt, Germany antibodies directed against at least three targets specified by them from Biocytogen's Project Integrum(also called HiTS Platform), which are generated by leveraging Biocytogen's proprietary RenMicePlatform.
  • Merck KGaA, Darmstadt, Germany will carry out feasibility tests and be responsible for further development and commercialization of the products if exercising an option.
  • Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.
  • Merck KGaA, Darmstadt, Germany holds the global rights to the Merck name and brand.

STORIA, AN INTEGRUM WORLDWIDE AGENCY, ACQUIRES DIGITAL AND WEB DEVELOPMENT DIVISION OF AGENCY SHELLSHOCK

Retrieved on: 
Wednesday, April 27, 2022
Magnet, Chalk, Operation Xcellerator, Population, Shellshock, Goal, KPI, PBS, Growth, ROI, Restitutio ad integrum, Ecosystem, Solution, CMO, Hell, Acquisition, Singani, Financial services, Tourism, Animal husbandry, Sales, Storia

LOS ANGELES, April 27, 2022 /PRNewswire/ -- Storia, a brand amplification agency, part of the Integrum Worldwide marketing agency collective, today announced it has acquired part of the assets of Shellshock in an all-cash asset purchase transaction. Specifically, Storia has acquired key team members, clients, and IP from Shellshock that will be used to further Storia's future growth. 

Key Points: 
  • Specifically, Storia has acquiredkey team members, clients, and IP from Shellshock that will be used to further Storia's future growth.
  • Integrum Worldwide has a forward thinking and expedited acquisition plan that it intends to execute over the upcoming eighteen months.
  • With this transaction and others expected to close before the end of 2022, Integrum Worldwide is working to quickly position itself as one of the foremost marketing agency collectives in the world.
  • Integrum Worldwide owns and operates best-of-breed marketing agencies, including Storia, a brand amplification agency providing services in branding and digitalmarketing, and Chalk, a full stack experiential marketing agency.

Biocytogen Expands Global Footprint with the Opening of Biocytogen Europe Innovation Center in Germany

Retrieved on: 
Monday, March 28, 2022
Restitutio ad integrum, Biotechnology, Research, Environment, CEO, European Molecular Biology Laboratory, Boehringer Ingelheim, Max Planck Society, Local government, COVID-19, BEIC, Patient, Merck, Antibody, Pharmaceutical industry, European, Bayer

BEIJING and HEIDELBERG, Germany, March 28, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as "Biocytogen") announced the opening of the Biocytogen Europe Innovation Center (BEIC) in Heidelberg, Germany.

Key Points: 
  • BEIJING and HEIDELBERG, Germany, March 28, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as "Biocytogen") announced the opening of the Biocytogen Europe Innovation Center (BEIC) in Heidelberg, Germany.
  • Local government representatives, clinical experts, and colleagues and collaborators from multi-national companies made speeches at the opening ceremony.
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs.
  • Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany.

Biocytogen Expands Global Footprint with the Opening of Biocytogen Europe Innovation Center in Germany

Retrieved on: 
Monday, March 28, 2022
Restitutio ad integrum, Biotechnology, Research, Environment, CEO, European Molecular Biology Laboratory, Boehringer Ingelheim, Max Planck Society, Local government, COVID-19, BEIC, Patient, Merck, Antibody, Pharmaceutical industry, European, Bayer

BEIJING and HEIDELBERG, Germany, March 28, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as "Biocytogen") announced the opening of the Biocytogen Europe Innovation Center (BEIC) in Heidelberg, Germany.

Key Points: 
  • BEIJING and HEIDELBERG, Germany, March 28, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as "Biocytogen") announced the opening of the Biocytogen Europe Innovation Center (BEIC) in Heidelberg, Germany.
  • Local government representatives, clinical experts, and colleagues and collaborators from multi-national companies made speeches at the opening ceremony.
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs.
  • Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany.

STORIA, AN INTEGRUM WORLDWIDE AGENCY, ACQUIRES AWARD-WINNING DIGITAL ADVERTISING AND CREATIVE AGENCY HELL'S CREATIVE

Retrieved on: 
Tuesday, December 14, 2021
Magnet, Becker, Solution, Singani, Chalk, Wpromote, Automation, Watson (computer), Acquisition, Entrepreneurship, Mediacom, Marketing, Adobe, IBM, Hell, Creative, Technology, Restitutio ad integrum, Financial services, Fashion, Sales, Film, Tourism, Storia

Integrum Worldwide owns and operates best-of-breed marketing agencies, including Storia, a brand amplification agency providing services in branding, digital marketing, and influencer marketing, and Chalk, a full stack experiential marketing agency.

Key Points: 
  • Integrum Worldwide owns and operates best-of-breed marketing agencies, including Storia, a brand amplification agency providing services in branding, digital marketing, and influencer marketing, and Chalk, a full stack experiential marketing agency.
  • I look forward to carrying the Hell's Creative legacy forward as part of the Storia and Integrum Worldwide collective.
  • Hell's Creative was co-founded in 2017 by Max Bidna and has grown to become one of the fastest growing and leading creative digital advertising firms in the United States.
  • Hell's Creative was recognized for achieving unmatched results by beating IBM Watson for "Best Creative Optimization" at the 2020 Drum Ad Awards.

Art Gives Back Big to Benefit St. Jude Children's Research Hospital at Basel

Retrieved on: 
Friday, December 3, 2021
Magnet, The Real Housewives of Orange County, CEO, Sale, Time, Paramount, Art Basel, Carroll Group, Partnership, Solution, Sculpture, Program, Restitutio ad integrum, St. Jude Children's Research Hospital, The Real Housewives of New York City (season 5), MIAMI, View, The Real Housewives, Berlin Art Week, Growth Enterprise Market, Life, NFT, Multimedia, Internet celebrity, Cobalt, Vogelsang, Singani, Nightclub, Interior design, Tourism, Online shopping

MIAMI BEACH, Fla., Dec. 3, 2021 /PRNewswire/ --To kick off Art Week, M2B Growth Enterprises & Integrum Worldwide gave back big, raising over $200,000 to benefit St. Jude Children's Research Hospital.

Key Points: 
  • MIAMI BEACH, Fla., Dec. 3, 2021 /PRNewswire/ --To kick off Art Week, M2B Growth Enterprises & Integrum Worldwide gave back big, raising over $200,000 to benefit St. Jude Children's Research Hospital.
  • Art met tech as NFT art pieces up for sale were displayed on a giant screen for all to see and purchase.
  • "I am extremely proud that we exceeded our fundraising goal of $200,000 for St. Jude Children's Research Hospital.
  • "Cube Art Fair is very excited to bring forth this unique art charity auction in support of St. Jude Children's Research Hospital.